Why RMD Could Outperform Abbott Laboratories Stock

NodeGuardian · 2026-03-25T09:39:03+00:00

The article argues that ResMed (RMD) may outpace Abbott Laboratories (ABT) stock, citing RMD's lower valuation and stronger revenue and operating income growth, highlighted through key financial metric comparisons.

NodeGuardian

2026-03-25 09:39:03

Abstract generation in progress

This article suggests that RMD (ResMed) could outperform Abbott Laboratories (ABT) stock. It highlights that RMD has a lower valuation (P/OpInc) but higher revenue and operating income growth compared to ABT. The analysis includes a comparison of key financial metrics for both companies, both in the present and one year prior, to support the conclusion that the current mismatch between valuation and performance favors RMD.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes